Effects of Transcranial Direct Current Stimulation (tDCS) and Cognitive Training on food cravings in people taking antipsychotic medication

CURRENT STATUS: ACCEPTED

Luiza Grycuk
Institute of Psychiatry Psychology and Neuroscience

k1778563@kcl.ac.uk Corresponding Author
ORCiD: https://orcid.org/0000-0003-2821-314X

Gemma Gordon
Institute of Psychiatry Psychology and Neuroscience Department of Psychological Medicine

Fiona Gaughran
Institute of Psychiatry Psychology and Neuroscience

Iain C. Campbell
Institute of Psychiatry Psychology and Neuroscience Department of Psychological Medicine

Ulrike Schmidt
Institute of Psychiatry Psychology and Neuroscience Department of Psychological Medicine

DOI:
10.21203/rs.2.10932/v1

SUBJECT AREAS
Psychiatry

KEYWORDS
schizophrenia, weight gain, transcranial direct current stimulation, approach bias modification training
Abstract
Background
Antipsychotic drug induced weight gain puts individuals with schizophrenia at increased cardiometabolic risk. As a potential intervention for this problem we describe the theoretical background and a protocol for a feasibility randomised controlled trial (RCT) of approach bias modification training (ABM) combined with real versus sham (placebo) transcranial direct current stimulation (tDCS). The aim of this trial is to obtain information that will guide decision making and protocol development in relation to a future large-scale RCT of ABM and tDCS in this group of patients and, secondly, to assess the preliminary efficacy ABM + tDCS treatment.

Methods
Thirty adults with a DSM-V diagnosis of schizophrenia or schizoaffective disorder treated with antipsychotic medication will be randomly allocated to receive 5 sessions that will combine ABM and real or sham tDCS, in a parallel group design. In this feasibility study a broad range of outcome variables will be examined and no primary outcomes have been defined. Measures will include food craving, psychopathology (e.g. symptoms of schizophrenia and depression), neuropsychological processes (such as attentional bias, and impulsiveness) and the tolerability and acceptability of tDCS. The feasibility of conducting a large-scale RCT of ABM + tDCS and appropriateness of tDCS as a treatment for antipsychotic drug induced weight gain will be evaluated by assessment of recruitment and retention rates, acceptability of random allocation, blinding success ( allocation concealment), completion of treatment sessions and research assessments (baseline, post-treatment and follow-up).

Discussion
The effect sizes generated and other findings from this trial will inform a future large-scale RCT with respect to decisions on primary outcome measures and other aspects of protocol development. In addition, results from this study will provide a preliminary indication of the efficacy of ABM + tDCS treatment for antipsychotic drug induced weight gain.

Background
Individuals taking antipsychotic medication show increased food craving, caloric intake and weight
gain which puts them at elevated risk for obesity-related conditions e.g. Type 2 diabetes and cardiovascular disease (1). People with schizophrenia have a higher mortality rate than the general population, mainly due to physical illnesses (2). Reducing the weight-related side effects of antipsychotic medication has the potential to improve health outcomes for this population.

Antipsychotic drug induced weight gain is well documented. A meta-analysis of 81 studies reported that, after 10 weeks of treatment, there was a mean weight increase of 4.45kg in patients receiving clozapine and 4.15kg for those receiving olanzapine (3). Fountaine, Taylor (4) showed that olanzapine treatment resulted in an estimated 345 kcal/day (18%) excess energy intake in 30 healthy male volunteers and 2.65kg increased body weight (over 15 days). Another study showed that 4-weeks of treatment with olanzapine was associated with an estimated increase of energy intake of 598 kcal/day (28%) in 10 male adolescents (5). These reports are broadly consistent with another review which concluded that patients with schizophrenia are more likely than matched controls to consume a diet poor in fibre and fruit and rich in saturated fat (6).

Treatments for antipsychotic drug induced weight gain include medication and interventions such as nutritional advice, cognitive behavioural therapy and exercise. Pharmacological interventions (e.g. fenfluramine, sibutramine, reboxetine, metformin, topiramate) are not very effective and can have significant side effects (7), whereas research on behavioural interventions has produced mixed results. In a 5-year naturalistic study of 82 outpatients newly started on clozapine, weight gain occurred despite active weight loss programmes involving diet and exercise (8). A meta-analysis of 20 trials of exercise interventions reported no significant effect on BMI (9), whereas a review of 13 studies investigating behavioural interventions reported a weight loss of 3.15% of initial weight, well below the 5-10% threshold considered sufficient to improve weight-related complications (10). Another meta-analysis of 17 studies concluded that behavioural interventions prevented and/or reduced antipsychotic associated weight gain (3.12kg less weight gain), however, weight was significantly improved only in outpatient trials (p<0.0001), but not in inpatient or mixed samples (p=0.09-0.96) (7). On the basis of these findings, there is a need for new treatments that target weight gain in people who take antipsychotic medication, especially those who may find it hard to
engage in exercise or therapy.

Human and animal studies suggest that antipsychotic drugs stimulate appetite by interacting with dopamine (D2), serotonin (5HT2a & 5HT2c), and histamine (H1, H2) receptors (1). Changes in peripheral hormones, e.g. leptin, ghrelin and adiponectin have been reported to be involved (11). Fat deposition may be facilitated by stress induced activation of the hypothalamic-pituitary-adrenal axis (12). Genetic predisposition may also play a part, e.g. antipsychotic drug induced weight gain is reported to be correlated with polymorphisms in the common promoter region for 5HT2c receptors (13) and polymorphisms near the melanocortin 4 receptor gene (MC4R4) (14).

As a result of altered appetite and increased susceptibility to hunger, people taking antipsychotic medication may develop disordered dietary behaviours (15). Brömel, Blum (16) showed that out of 12 patients started on clozapine, 9 reported increased appetite and 2 developed binge eating episodes. In another study of 74 patients on either olanzapine or clozapine, 37 screened positively for binge eating, with 9 fulfilling criteria for binge eating disorder and 5 for bulimia nervosa (17). Additionally, patients who screened positively for binge eating showed higher BMIs and higher BMI gains during treatment. These results suggest, that modifying food cravings and /or food consumption may affect antipsychotic drug induced weight gain.

The observations described above are consistent with evidence from neuroimaging studies. An fMRI study of 25 individuals after 1 week of olanzapine treatment showed enhanced anticipatory and consummatory responses to food rewards and decreased responsivity to food consumption (18). Another study of 25 individuals after 16-weeks olanzapine treatment reported increased sensitivity to appetitive stimuli in insular cortices, amygdala and cerebellum, compared with controls (19). There was also an increased response to appetite-related stimuli from baseline to post-treatment, in the frontal cortex, fusiform gyrus, amygdala and insula.
Neural activity in certain brain areas can be enhanced or reduced by neuromodulation procedures e.g. repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS). These non-invasive brain stimulation methods have demonstrated therapeutic potential in major depressive disorder (20), bipolar affective disorder (21), obsessive compulsive disorder, generalised anxiety disorder and substance use disorder (22). They have also been trialled and well received in people with schizophrenia, helping to alleviate auditory verbal hallucinations and improving negative symptoms (22).

Brain stimulation may also be a promising tool for reducing food cravings (23) which could be used to treat antipsychotic induced weight gain. The most common target of neuromodulation is the dorsolateral prefrontal cortex (dPLFC) which has been associated with control of eating via possible mechanisms of reward valuation, attention and inhibitory control (24). For example, one session of high-frequency rTMS delivered to the left dPLFC lowered cue-induced food cravings in people with bulimic disorder (25, 26) and tDCS applied to the dPLFC reduced food cravings in healthy participants (27, 28) and the desire to eat in overweight and obese participants (29).

Another potential intervention for antipsychotic drug induced weight gain is Approach Bias Modification training (ABM). ABM is a computer training aiming to modify implicit attention biases through teaching participants to avoid negative stimuli by directing their attention to neutral or positive stimuli (30). A review of 12 meta-analyses concluded that a course of ABM sessions can shift target biases in adults, with moderate effect sizes (31). ABM can also be effective at re-training approach bias to appetitive cues such food and alcohol (32). ABM significantly reduced approach tendencies and attention towards food cues in a sample of people who binge eat (33), and reduced eating disorders symptoms in a sample of people with either bulimia nervosa or binge eating disorder.
ABM may be enhanced by neuromodulation methods which can increase neuroplasticity (35) and potentially aid learning aimed at avoiding high-calorie foods. This has been reported by Heeren, Baeken (36), who found that neuromodulation boosted the effects of cognitive training aimed at reducing cognitive bias and improving response inhibition. Den Uyl, Gladwin (37) conducted 4 sessions of concurrent ABM and tDCS over 7 days on alcohol-dependent inpatients. Although no enhanced effect of tDCS on ABM training was found, a reduced probability of relapse at the one-year follow-up was noted in the real tDCS group compared to sham. This indicates that combined tDCS and ABM can potentially have a stronger effect on reducing food cravings than either of the treatments alone.

In summary, research shows that dietary behaviours can be altered by neuromodulation methods as well as ABM training. To our knowledge, this will be the first time that both of these interventions will be combined and applied in people taking antipsychotic medication. The proposed feasibility study is an RCT comparing ABM training combined with real (active) or sham (placebo) anodal tDCS to the dIPFC in individuals with schizophrenia who take antipsychotic medication. We will assess recruitment, attendance, retention and follow-up rates that will inform the development of a large-scale RCT. Changes to food cravings and eating behaviours as well as other clinical outcomes will be measured before and after the treatment intervention and at a 2-week follow-up.

Aims

The aims of this study are to:

(1) establish the feasibility of conducting a large-scale RCT of [ABM + tDCS] in patients with
schizophrenia who take antipsychotic medication: this will involve assessing safety (adverse events), recruitment, attendance and retention rates;

(2) determine the best instruments for measuring outcomes in a future full trial by examining the quality, completeness and variability in the data;

(3) estimate the treatment effect sizes and standard deviations for outcome measures to inform the sample size calculation for a larger-scale RCT;

(4) explore participants’ views on the acceptability, credibility, tolerability and experience of [ABM + tDCS];

(5) obtain information about participants’ willingness to undergo random allocation to 5 sessions of ABM combined with real or sham tDCS;

Based on neuromodulation studies conducted by our group (38, 39) and others (40-42) in people who experience food cravings, we predict that, compared to [ABM + sham tDCS] treatment, 5 sessions of [ABM + real tDCS] applied to the dIPFC will:

(1) decrease approach bias towards food stimuli;

(2) decrease state food craving after cue exposure;

(3) decrease trait food craving from baseline to post-assessment;

(4) be considered by patients as an acceptable and useful treatment for antipsychotic induced weight gain.

Methods

Design
This is a parallel group, double-blind, two-arm RCT. Participants will be randomly allocated to receive 5 sessions of either [ABM + real tDCS] (treatment group) or [ABM + sham tDCS] (control group) over 3-4 weeks, delivered in addition to treatment as usual. Outcomes will be measured at baseline, post-treatment, and at 2-week follow-up. Participants in the control group will be offered the opportunity to receive [ABM + real tDCS] at the end of the study. The protocol is outlined in Fig.1, and Table 1 gives details of assessments and time points.

Setting

The study will be conducted at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) and at inpatient and community services at the South London and Maudsley NHS Foundation Trust (SLaM).

Ethical approval and trial registration

Ethical approval for the study was obtained from the Oxford B Research Ethics Committee (REC, ref: 19/SW/0095). The study is registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry (registration number: ISRCTN13280178).

Figure 1. Schematic Diagram of the study protocol

Participants and recruitment

Participants will be recruited from inpatient and community services at the South London and Maudsley NHS Foundation Trust (SLaM), through websites (such as IoPPN), through social media platforms (such as Eating Disorders Unit official Twitter account) and through the Consent 4 Contact
SLaM initiative (43). Participants will be paid £90 for their time and effort.

**Inclusion criteria**

Male or female participants will be included if they have a current DSM-V diagnosis of schizophrenia or schizoaffective disorder, are aged 18-65 years and have been on a stable dose of antipsychotic medication for at least 6 weeks prior to study enrolment.

**Exclusion criteria**

Participants will be excluded if they: suffer from any significant /unstable co-morbid medical or psychiatric disorders (e.g. substance dependence); are on a dose of antidepressant medication that has not been stable for at least 6 weeks; are allergic to any of the foods used in the study; cannot understand verbal or written English. A tDCS safety questionnaire will be administered and individuals will be excluded if they: have a history of epileptic seizures, stroke or brain injury; have any implanted metal devices in the head; suffer from frequent or severe headaches or dizziness; are pregnant.

**Sample size**

As this is a feasibility study, no a priori sample calculation has been conducted. This study aims to provide effect sizes on which future large-scale studies can be based. Total sample sizes of n=24 to n=50 have been recommended for feasibility trials with a primary outcome measured on a continuous scale, mainly because estimates of the standard deviation for normally distributed variables tend to stabilise around this size (44, 45). We have chosen a total sample size of n=30 (which exceeds the lower end recommended for feasibility trials).
Randomisation

Generation and implementation of the randomisation sequence will be conducted independently from the trial team by a King’s College researcher using Sealed Envelope, an online randomisation tool (46). Once the baseline assessment has been conducted and the patient is recruited and has consented to the trial, she/he will be allocated to one of the two intervention arms in a ratio of 1:1. Group allocation will be communicated via phone, email or in a sealed non-transparent envelope to the appropriate member of the research team for each participant.

Intervention

Study procedures

In both groups, participants will receive 5 sessions of [ABM + real /sham tDCS] over 3-4 weeks. ABM and tDCS will be delivered at the same time, i.e. participants will engage in the ABM whilst receiving brain stimulation. Each session will last approximately 40 minutes, including preparation time, 20 minutes of [ABM + tDCS] and questionnaire administration. The ABM will start 1 minute after the start of the brain stimulation, to allow participants to get used to the brain stimulation. Thereafter, ABM will take place over 15 minutes and brain stimulation will then continue for a further 4 minutes. Throughout the study, participants will be able to access or continue treatment as usual as recommended by their treating team.

ABM training

The ABM programme is based on a modified version of the Food Approach /Avoidance Task (F-AAT). In the F-AAT task, participants are shown pictures of food and control (i.e. neutral household and office) items. They are required to pull (pictures grow bigger) or push (pictures grow smaller) a joystick in
response to the outer frame of the picture (round vs. rectangular), irrespective of the picture content. The ABM task adopts an implicit learning paradigm by presenting all food pictures in the “push” (i.e. avoid) format. The study procedure for ABM administration is in accord with a protocol paper (47), with updated images of foods and non-edible objects from a food-pictures database (48).

**tDCS**

TDCS (both real and sham) will be delivered using a neuroConn® DC-STIMULATOR device at a constant current of 2 mA (with a 10-second fade in/out) using two 25cm² surface sponge electrodes soaked in a sterile saline solution (0.9% sodium chloride). The anode will be placed over the right dlPFC and the cathode over the left dlPFC. The stimulation site will correspond to the F3 location based on the International 10-20 system (49). In the real tDCS group, current will be delivered for the whole duration of the stimulation (20 minutes). In the sham (placebo) tDCS group, current will automatically turn off after 30 seconds.

**Safety**

Study procedures and parameters are in accord with safety and application guidelines for tDCS (50). Treatment will be delivered by personnel trained in tDCS administration. A case record form for each trial participant will be kept to monitor session attendance and any side effects or adverse events according to prespecified criteria. Any protocol violations will also be recorded there. To ensure safety, participants’ blood pressure and pulse will be monitored before and after each stimulation. TDCS is generally well-tolerated and is associated with relatively minor side effects. According to the review of 567 tDCS sessions adverse events (and occurrence rates) included: tingling sensation (70.6%), moderate fatigue (35.3%), light itching sensation under the stimulation electrodes (30.4%), headache (11.8%), nausea (2.9%) and insomnia (0.98%) (51). Another review of 209 tDCS studies
found similar rates of adverse events in both real and sham stimulation groups (52). In the event of mild side effects (e.g. a slight headache) participants will not be withdrawn, but will be able to discontinue tDCS treatment if they wish. TDCS will be immediately halted if the participant experiences a more serious adverse event or if any other indicators of serious medical risk emerge. Treatment will only be restarted if it is deemed safe to continue by a medical professional. Standard King’s College London insurance and NHS indemnity arrangements will apply to this study.

Table 1. Study schedule of enrolment, interventions and assessments

Procedure

A flowchart outlining study procedures is presented in Fig. 1. Table 1 presents the time schedule of enrolment, interventions and assessments, consistent with the figure provided in the SPIRIT Statement (2013) (65) recommendations for reporting protocols (see Additional File 1 for SPIRIT checklist).

Screening

Potential participants will be referred by their clinician or will self-refer. Researchers will screen participants for eligibility. Screening questionnaires include a tDCS safety screen, and a short inclusion /exclusion study specific screen, including an assessment of medical and psychiatric history, and medication dosage and stability. In line with the CONSORT guidelines (53, 54), we will record the number and reasons for any participants we must exclude, or any who decline consent or withdraw from the study.

Baseline assessment
Once eligibility has been confirmed, the participant’s written informed consent will be obtained by the researcher. Participants will be asked to complete a number of questionnaires and experimental procedures assessing eating behaviours and mood, as well as computer tasks that assess attention bias towards food cues. Once the baseline assessment is complete, participants will be randomly allocated to the treatment [ABM + real tDCS] or control [ABM + sham tDCS] group.

**Post-treatment assessment**

Post-treatment assessment will take place after the last treatment session and include the same elements as the baseline assessment. Blinding success will be evaluated by asking participants and researchers to guess the treatment allocation.

**Follow-up**

Two weeks after post-treatment assessment, a follow-up session will be conducted. This short session will consist of questions regarding mood, food cravings and eating behaviours. Participants’ weight will be measured.

**Measures**

**Screening measures**

A tDCS safety screen will be conducted to check for contraindications to tDCS.

**Outcome measures**
Since this is a feasibility study, a broad range of outcome measures are included to determine which are most sensitive to detecting a treatment effect. This will enable us to determine primary outcome(s) for a future large-scale RCT.

Clinical outcomes related to eating behaviours

(1) Questionnaires including Eating Disorder Examination Questionnaire (EDE-Q) (55) and Food Cravings Questionnaire-Trait-Reduced (FCQ-T-r) (56) will be administered at baseline and post-treatment. The FCQ-T-r will also be administered at a 2-week follow-up.

(2) Food tasks including the Food Challenge Task (FCT) (38) examining cue-induced food craving and the Taste Test measuring actual food consumption will be administered at baseline and post-treatment. Within each session, Visual analogue scales (VASs) regarding current experiences (level of hunger, feeling full, urge to eat, feeling low, level of tension, level of stress, level of anxiety) will be completed before and after the food tasks.

(3) Computer tasks including the Food Approach-Avoidance Task (F-AAT) (33) and the Stimulus Response Compatibility Task (SRC) (57) measuring approach bias towards high-calorie food items will be administered at baseline and post-treatment.

Other clinical outcomes

(1) Questionnaires assessing: depression - Depression, Anxiety and Stress Scale (DASS-21) (58); cognitive deficits - Montreal Cognitive Assessment (MoCA) (59); and impulsivity - Barratt Impulsiveness Scale (BIS-11) (60); will be administered at baseline and post-treatment. The DASS-21 will also be administered at a 2-week follow-up.

(2) Symptoms of schizophrenia will be assessed by the Simplified Negative and Positive Symptoms Scale (SANS) (61) and Positive and Negative Syndrome Scale (PANSS) (62) at baseline and post-treatment.
Interview (SNAPSI) (61) and rated using the Positive and Negative Syndrome Scale (PANSS-6) (62) at baseline and post-treatment.

**Intervention related outcomes**

(1) Acceptability of the intervention will be measured as follows: (a) before and after each treatment session by collecting VAS scores on the levels of tension, stress and anxiety; (b) before and after each treatment session by asking about any comments about the treatment; (c) at the end of the study, by asking participants if they would like to take part in a therapeutic trial of tDCS if this was available; (d) by the number of recruited participants.

(2) Treatment tolerability will be measured after each session by a VAS assessing levels of discomfort.

**Blinding**

This will be a double-blind study, where participants and researchers conducting assessments and delivering tDCS are blinded to treatment allocation. Sufficient blinding will be ensured by utilising a parallel design and a built-in neuroConn® DC-STIMULATOR blinding feature. With this, real and sham stimulations are assigned different codes, which the researcher enters into the device to start the stimulation. The real stimulation continues for 20 minutes, whereas the sham stimulation stops after 30 seconds, which triggers the same sensations on the skin (to improve blinding). To assess whether allocation concealment has been successful, participants and researchers will be asked to guess the treatment allocation at the end of the tDCS treatment and to indicate how certain they are of this guess. Participants will be debriefed and unblinded to group allocation at the end of the study. At that time, participants in the sham condition will be offered [ABM + real tDCS] treatment following the protocol as described above.
Analyses

Feasibility

The decision as to whether to progress the study to a future large-scale RCT will be based on a number of criteria. These include the number of patients we are able to recruit, the proportion of patients retained, the proportion of patients completing the real and sham [ABM + tDCS] intervention, the acceptability and tolerability of the tDCS and the effect sizes of treatment outcomes. At the end of the study, these factors will be used to decide the case for progressing to a substantive RCT.

Clinical outcomes

Analyses will use the intention-to-treat principle. Descriptive statistical analyses and graphical methods will be used to determine quality, completeness and variability of the outcome measures. The size of the treatment effect on each outcome measure (questionnaires, tasks) will be the difference in outcome data between those in the two treatment conditions at post-treatment and follow-up. Group differences will be estimated using linear mixed effects regression models, controlling for the baseline level of the outcome. The aim of the analysis is to establish a suitably precise effect size for the primary outcome at the post-treatment assessment in a future large-scale RCT.

Discussion
Antipsychotic drug induced weight gain can affect physical health of people with schizophrenia. Additionally, it can cause individuals to discontinue medication and hence predispose them to relapse (1). Interventions to prevent weight gain have limited effectiveness in acutely unwell patients who may find it hard to engage in diet or exercise behaviours (7). There is a need for treatments to prevent weight gain that are easily accessible and can be utilised in various settings.
Non-invasive brain stimulation methods, e.g. tDCS, can be used to target brain areas such as the dlPFC which are associated with cognitive control (including eating) (24). These have the potential to reduce antipsychotic drug induced weight gain, e.g. by decreasing food cravings. TDCS can be combined with ABM training to strengthen its effects on retraining approach bias towards high calorie foods. We have described the protocol for a feasibility trial that will inform future studies and add to the evidence of brain-directed interventions for antipsychotic drug induced weight gain.

Strengths of the study include use of combined neuromodulation and cognitive training. It has been reported that behaviours and cognitions undertaken during or following the tDCS can impair or abolish the effects of stimulation (63). Administering two interventions concurrently will remove any cognitive interferences and ensure uniform treatment. The protocol is also designed to measure the possible mechanisms of action e.g. on attention bias and impulsiveness, as well as on clinical symptoms. The protocol adheres to guidance on the optimal conduct of neuromodulation trials (53, 64, 65).

Possible challenges relate to recruitment /attrition. People with schizophrenia may be ambivalent about receiving tDCS because they may associate it with electroconvulsive therapy. Additionally, people who experience persecutory delusions may not want to undergo the treatment. As participants will be recruited via clinical teams, the aforementioned beliefs may also apply to the clinicians (i.e. the perceived value and cost of the treatment) and this may affect recruitment. To mitigate this, special care will be taken to explain the practical and technical nature of the tDCS to both service users and clinicians. Previous neuromodulation studies in patients with schizophrenia have showed good recruitment rates and adherence to treatment, however, it is unclear whether this can be replicated in the context of weight management. There may be other challenges, e.g. if the participant believes they are receiving sham, or if the treatment is too uncomfortable or too tiring. It is not clear whether participants will be able to distinguish between the real and sham treatment and what impact this will
have on attrition rates. TDCS blinding is generally good, e.g. in an RCT for major depressive disorder, TDCS blinding was comparable to that of sertraline (66). Sensations felt during treatment may interfere with blinding, tDCS can occasionally result in mild discomfort during administration (i.e. tingling, itching or skin redness). However, based on the review of 209 studies, these side effects occur at a similar rate in both real and sham groups (67).

In summary, combined tDCS and ABM is a promising brain-directed treatment for reducing food cravings and food consumption. This innovative feasibility RCT will assess the acceptability and efficacy of this intervention in people with schizophrenia. It will provide a basis for development of future large-scale RCTs and, if results are positive, will provide support for the implementation of it as a treatment.

**Trial status**

Participant recruitment and data collection for this study began in June 2019. Recruitment will be completed in May 2020 (approximately). The most recent version of the protocol (v1.0 dated 4 April 2019) was approved by the Oxford B REC (ref: 19/SW/0095) on 04 June 2019. Any substantial protocol amendments will be communicated to investigators via email and to other parties as required. Amendments to the study protocol will be reported in publications reporting the study outcomes.

**Abbreviations**

5HT2a: 5-hydroxy-tryptamine receptor 2a; 5HT2c: 5-hydroxy-tryptamine receptor 2c; ABM: Approach bias modification training; BIS-11: Barratt Impulsiveness Scale; BRC: Biomedical Research Centre; CONSORT: Consolidated Standards of Reporting Trials; D2: dopamine receptor D2; DASS-21: Depression, anxiety and stress scale; dlPFC: dorsolateral prefrontal cortex; DSM-V: Diagnostic and Statistical Manual for Mental Disorders, Fifth edition; EDE-Q: Eating disorder examination questionnaire; F-AAT: Food Approach /Avoidance Task; FCQ-T-r: Food cravings
questionnaire-trait-reduced; FCT: Food challenge task; fMRI: functional magnetic resonance imaging; H1: histamine receptor H1; H2: histamine receptor H2; IoPPN: Institute of Psychiatry, Psychology and Neuroscience; ISRCTN: International Standard Randomised Controlled Trial Number; MC4R4: Melanocortin 4 receptor gene; MoCA: Montreal cognitive assessment; NIHR: National Institute for Health Research; PANSS-6: Positive and Negative Syndrome Scale; RCT: Randomised controlled trial; REC: Research ethics committee; rTMS: Repetitive transcranial magnetic stimulation; SLaM: South London and Maudsley NHS Foundation Trust; SNAPS1: Simplified Negative and Positive Symptoms Interview; SPIRIT: Standard Protocol Items: Recommendations for Intervventional Trials; SRC: Stimulus response compatibility task; tDCS: Transcranial direct current stimulation; VAS: Visual analogue scale;

Declarations

Acknowledgments

Not applicable

Funding

This work is supported by funding from the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust (SLaM) and King’s College London. Luiza Grycuk, Fiona Gaughran, Iain Campbell and Ulrike Schmidt receive salary support from the BRC. FG is, in part, funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research & Care Funding scheme and by the Maudsley Charity. Gemma Gordon is funded by a BRC PhD studentship. Ulrike Schmidt is supported by an NIHR Senior Investigator Award. The funder was not involved in the study design and writing of this trial protocol paper, and will not be involved in the collection and analysis of data, nor the writing of the study report. The funders will not have ultimate authority over these activities. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Data management

Participant data will be anonymised and all anonymised data will be stored electronically on a password protected computer at the IoPPN. All trial data will be stored in line with the General Data Protection Regulation (GDPR) 2018. Hard copies of participant-related data will be kept in locked cabinets at the IoPPN, King’s College London. The final trial data set will not be accessed by anyone other than members of the research team.

It is intended that the results of this feasibility study will be reported and disseminated at national and international conferences. Research findings may also be disseminated through internal newsletters and publications.

Owing to the size and nature of this small-scale feasibility study, a data monitoring committee was not deemed to be required. There are no scheduled interim analyses and this trial may be prematurely discontinued by the Chief Investigator on the basis of new safety information.

Availability of data and material

Not applicable

Authors’ Contributions

LG, GG, US, ICC and FG made significant contributions to the design and drafting of this protocol. LG drafted the original manuscript, GG, US, ICC and FG made revisions to this manuscript. US is the principal investigator of the study. All authors have approved the final manuscript and accept
responsibility for the accuracy and integrity of this work. No professional writers were involved in this study protocol, nor will be involved in the study report write-up.

**Ethics approval and consent to participate**

The protocol version 1 dated 04/04/2019 was approved by the Oxford B Research Ethics Committee (REC, reference number: 19/SW/0095) and is a registered clinical trial under the International Standard Randomised Controlled Trial Number (ISRCTN) registry (registration number: ISRCTN13280178). The written informed consent of all participants will be collected by the investigators before performing any study-specific procedure.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab. 2014;25(11):593-600.

2. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177(3):212-7.

3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.
4. Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity. 2010;18(8):1646-51.

5. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry. 2002;159(6):1055-7.

6. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013;47(2):197-207.

7. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140(1-3):159-68.

8. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157(6):975-81.

9. Firth J, Cotter J, Elliott R, French P, Yung A. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 2015;45(7):1343-61.

10. Bonfioli E, Berti L, Goss C, Muraro F, Burti L. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry. 2012;12(1):78.

11. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127(3):210-51.
12. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand. 1999;100(1):3-16.

13. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor– 759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2005;133(1):97-100.

14. Malhotra AK, Correll CU, Chowdhury NI, Müller DJ, Gregersen PK, Lee AT, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69(9):904-12.

15. Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, Roy MA, et al. Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring). 2008;16(8):1780-7.

16. Brömel T, Blum W, Ziegler A, Schulz E, Bender M, Fleischhaker C, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry. 1998;3(1):76.

17. Theisen FM, Linden A, König IR, Martin M, Remschmidt H, Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm (Vienna). 2003;110(1):111-21.

18. Mathews J, Newcomer JW, Mathews JR, Fales CL, Pierce KJ, Akers BK, et al. Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry. 2012;69(12):1226-37.

19. Stip E, Lungu OV, Anselmo K, Letourneau G, Mendrek A, Stip B, et al. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry. 2012;2:e128.

20. Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, et al. Transcranial direct
current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016;208(6):522-31.

21. Donde C, Neufeld NH, Geoffroy PA. The Impact of Transcranial Direct Current Stimulation (tDCS) on Bipolar Depression, Mania, and Euthymia: a Systematic Review of Preliminary Data. Psychiatr Q. 2018;89(4):855-67.

22. Kekic M, Boysen E, Campbell IC, Schmidt U. A systematic review of the clinical efficacy of transcranial direct current stimulation (tDCS) in psychiatric disorders. J Psychiatr Res. 2016;74:70-86.

23. Dalton B, Campbell IC, Schmidt U. Neuromodulation and neurofeedback treatments in eating disorders and obesity. Curr Opin Psychiatry. 2017;30(6):458-73.

24. Dunlop KA, Woodside B, Downar J. Targeting neural endophenotypes of eating disorders with non-invasive brain stimulation. Front Neurosci. 2016;10:30.

25. Van den Eynde F, Claudino AM, Mogg A, Horrell L, Stahl D, Ribeiro W, et al. Repetitive transcranial magnetic stimulation reduces cue-induced food craving in bulimic disorders. Biol Psychiatry. 2010;67(8):793-5.

26. Van den Eynde F, Guillaume S, Broadbent H, Campbell I, Schmidt U. Repetitive transcranial magnetic stimulation in anorexia nervosa: a pilot study. Eur Psychiatry. 2013;28(2):98-101.

27. Fregni F, Orsati F, Pedrosa W, Fecteau S, Tome FA, Nitsche MA, et al. Transcranial direct current stimulation of the prefrontal cortex modulates the desire for specific foods. Appetite. 2008;51(1):34-41.

28. Goldman RL, Borckardt JJ, Frohman HA, O’Neil PM, Madan A, Campbell LK, et al. Prefrontal cortex transcranial direct current stimulation (tDCS) temporarily reduces food cravings and increases the self-reported ability to resist food in adults with frequent food craving. Appetite. 2011;56(3):741-6.
29. Montenegro RA, Okano AH, Cunha FA, Gurgel JL, Fontes EB, Farinatti PT. Prefrontal cortex transcranial direct current stimulation associated with aerobic exercise change aspects of appetite sensation in overweight adults. Appetite. 2012;58(1):333-8.

30. Beard C, Sawyer AT, Hofmann SG. Efficacy of attention bias modification using threat and appetitive stimuli: A meta-analytic review. Behav Ther. 2012;43(4):724-40.

31. Jones EB, Sharpe L. Cognitive bias modification: a review of meta-analyses. J Affect Disord. 2017;223:175-83.

32. Kakoschke N, Kemps E, Tiggemann M. Approach bias modification training and consumption: A review of the literature. Addict Behav. 2017;64:21-8.

33. Brockmeyer T, Hahn C, Reetz C, Schmidt U, Friederich HC. Approach bias and cue reactivity towards food in people with high versus low levels of food craving. Appetite. 2015;95:197-202.

34. Brockmeyer T, Friederich HC, Kuppers C, Chowdhury S, Harms L, Simmonds J, et al. Approach bias modification training in bulimia nervosa and binge-eating disorder: A pilot randomized controlled trial. Int J Eat Disord. 2019;52(5):520-9.

35. Stagg CJ, Nitsche MA. Physiological basis of transcranial direct current stimulation. Neuroscientist. 2011;17(1):37-53.

36. Heeren A, Baeken C, Vanderhasselt M-A, Philippot P, De Raedt R. Impact of anodal and cathodal transcranial direct current stimulation over the left dorsolateral prefrontal cortex during attention bias modification: an eye-tracking study. PLoS One. 2015;10(4):e0124182.

37. Den Uyl TE, Gladwin TE, Rinck M, Lindenmeyer J, Wiers RW. A clinical trial with combined transcranial direct current stimulation and alcohol approach bias retraining. Addict Biol.
38. Kekic M, McClelland J, Bartholdy S, Boysen E, Musiat P, Dalton B, et al. Single-Session Transcranial Direct Current Stimulation Temporarily Improves Symptoms, Mood, and Self-Regulatory Control in Bulimia Nervosa: A Randomised Controlled Trial. PLoS One. 2017;12(1):e0167606.

39. Kekic M, McClelland J, Campbell I, Nestler S, Rubia K, David AS, et al. The effects of prefrontal cortex transcranial direct current stimulation (tDCS) on food craving and temporal discounting in women with frequent food cravings. Appetite. 2014;78:55-62.

40. Jansen JM, Daams JG, Koeter MW, Veltman DJ, van den Brink W, Goudriaan AE. Effects of non-invasive neurostimulation on craving: a meta-analysis. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2472-80.

41. Lowe CJ, Hall PA, Staines WR. The effects of continuous theta burst stimulation to the left dorsolateral prefrontal cortex on executive function, food cravings, and snack food consumption. Psychosom Med. 2014;76(7):503-11.

42. Song S, Zilverstand A, Gui W, Li H-j, Zhou X. Effects of single-session versus multi-session non-invasive brain stimulation on craving and consumption in individuals with drug addiction, eating disorders or obesity: A meta-analysis. Brain Stimul. 2018.

43. Consent4Contact SLaM. 2019. https://www.slam.nhs.uk/research/patient-involvement/current-opportunities/consent-for-contact. [Accessed 14 May 2019].

44. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10(2):307-12.

45. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287-91.

46. Sealed Envelope Ltd. 2019. Simple randomisation service.
https://www.sealedenvelope.com/simple-randomiser/v1/. [Accessed 9 May 2019].

47. Brockmeyer T, Schmidt U, Friederich H-C. The ABBA study–approach bias modification in bulimia nervosa and binge eating disorder: study protocol for a randomised controlled trial. Trials. 2016;17(1):466.

48. Blechert J, Meule A, Busch NA, Ohla K. Food-pics: an image database for experimental research on eating and appetite. Front Psychol. 2014;5:617.

49. Jasper HH. The 10-20 electrode system of the International Federation. Electroencephalogr Clin Neurophysiol. 1958;10:371-5.

50. Brunoni AR, Nitsche MA, Bolognini N, Bikson M, Wagner T, Merabet L, et al. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul. 2012;5(3):175-95.

51. Poreisz C, Boros K, Antal A, Paulus W. Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain research bulletin. 2007;72(4-6):208-14.

52. Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. International Journal of Neuropsychopharmacology. 2011;14(8):1133-45.

53. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol. 2001;1(1):2.

54. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18.

55. Fairburn CG, Beglin S. Eating disorder examination questionnaire. Cognitive behaviour therapy and eating disorders. 3092008. p. 313.

56. Meule A, Hermann T, Kübler A. A short version of the Food Cravings Questionnaire—Trait: the FCQ-T-reduced. Front Psychol. 2014;5:190.

57. De Houwer J, Crombez G, Baeyens F, Hermans D. On the generality of the affective Simon effect. Cogn Emot. 2001;15(2):189-206.
58. Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995;33(3):335-43.

59. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-9.

60. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768-74.

61. Østergaard SD, Opler MG, Correll CU. Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI). Innov Clin Neurosci. 2017;14(11-12):68.

62. Østergaard SD, Lemming OM, Mors O, Correll CU, Bech P. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand. 2016;133(6):436-44.

63. Horvath JC, Forte JD, Carter O. Quantitative Review Finds No Evidence of Cognitive Effects in Healthy Populations From Single-session Transcranial Direct Current Stimulation (tDCS). Brain Stimul. 2015;8(3):535-50.

64. Brunoni AR, Fregni F. Clinical trial design in non-invasive brain stimulation psychiatric research. Int J Methods Psychiatr Res. 2011;20(2):e19-e30.

65. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-7.

66. Brunoni AR, Schestatsky P, Lotufo PA, Bensenor IM, Fregni F. Comparison of blinding effectiveness between sham tDHS and placebo sertraline in a 6-week major depression randomized clinical trial. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2014;125(2):298-305.

67. Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. The
Table 1. Study schedule of enrolment, interventions and assessments

| Timepoint                                                                 | Screen Visit (all participants) | Baseline (all participants) | Training: ABM + real tDCS | Training: ABM + sham tDCS | Post-assessment (all participants) | F (p) |
|--------------------------------------------------------------------------|---------------------------------|-----------------------------|---------------------------|---------------------------|-----------------------------------|-------|
| Participant information sheet, inclusion/exclusion criteria and tDCS safety screen | X                              |                             |                           |                           |                                   |       |
| Informed consent                                                        |                                 |                             |                           |                           |                                   | X     |
| Demographic information                                                  |                                 | X                           |                           |                           |                                   |       |
| Questionnaires                                                           |                                 | X                           |                           |                           |                                   | X     |
| Food related tasks                                                       |                                 | X                           |                           |                           |                                   | X     |
| Approach bias assessment tasks                                           |                                 | X                           |                           |                           |                                   |       |
| Pre-[ABM + tDCS] measures: multiple VASs, blood pressure and pulse       |                                 | X                           |                           |                           |                                   |       |
| Anodal real tDCS to dlPFC                                                |                                 | X                           |                           |                           |                                   |       |
| Anodal sham tDCS to dlPFC                                                |                                 |                             |                           | X                         |                                   |       |
| Approach bias modification training                                       |                                 | X                           |                           |                           |                                   |       |
| Post-[ABM + tDCS] measures: multiple VASs, blood pressure and pulse       |                                 |                             |                           |                           |                                   |       |
| Tolerance, discomfort and side effects of tDCS                           |                                 | X                           |                           |                           |                                   |       |
| Acceptability questionnaire                                              |                                 |                             |                           |                           |                                   | X     |
| Blinding assessment questionnaire                                        |                                 |                             |                           |                           |                                   | X     |
| Follow-up questionnaires                                                 |                                 |                             |                           |                           |                                   |       |
| Unblinding                                                               |                                 |                             |                           |                           |                                   |       |
Additional File Legend

Additional file 1: populated SPIRIT checklist, consistent with the SPIRIT Statement (2013) (65) recommendations for reporting protocols. (DOCX 124 KB)

Figures

Figure 1

Schematic Diagram of the study protocol

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

Additional File 1.doc